Company Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
The company was founded in 2018 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | David Hung |
Contact Details
Address: 1500 Broadway, Suite 1401 New York, New York 10036 United States | |
| Phone | 332 208 6102 |
| Website | nuvationbio.com |
Stock Details
| Ticker Symbol | NUVB |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001811063 |
| CUSIP Number | 67080N101 |
| ISIN Number | US67080N1019 |
| Employer ID | 85-0862255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David T. Hung M.D. | Founder, President, Chief Executive Officer and Chairman |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
| Philippe Sauvage | Chief Financial Officer and Principal Financial Officer |
| Moses Makunje CPA | Vice President of Finance and Principal Accounting and Financial Officer |
| Stephen Dang | Vice President of Legal and Secretary |
| Stacy Markel | Chief People Officer |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Kerry A. Wentworth | Chief Regulatory Officer |
| Colleen Sjogren | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 6, 2024 | SCHEDULE 13G/A | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Oct 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 7, 2024 | 8-K | Current Report |
| Sep 10, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 15, 2024 | EFFECT | Notice of Effectiveness |
| Aug 15, 2024 | 424B3 | Prospectus |